Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Cridanimod with Progestin in Endometrial Carcinoma
NCT03077698Phase 2Terminated
- Sponsor
- Xenetic Biosciences, Inc.
- Start
- Jun 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cridanimod in endometrial carcinoma, sponsored by Xenetic Biosciences, Inc.. Started Jun 2017; status: terminated.
02
Drugs
cridanimod
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT03077698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03077698.